IRIS
TISEO, Marcello
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.084
AS - Asia 16.615
EU - Europa 9.595
SA - Sud America 2.710
AF - Africa 932
OC - Oceania 28
Continente sconosciuto - Info sul continente non disponibili 8
AN - Antartide 1
Totale 46.973
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.591
SG - Singapore 6.323
CN - Cina 3.467
VN - Vietnam 2.674
IT - Italia 2.400
BR - Brasile 2.032
IE - Irlanda 1.671
SE - Svezia 1.408
HK - Hong Kong 1.340
BD - Bangladesh 1.003
DE - Germania 718
FR - Francia 718
FI - Finlandia 625
ZA - Sudafrica 601
NL - Olanda 554
IN - India 392
GB - Regno Unito 320
RU - Federazione Russa 293
TR - Turchia 265
AR - Argentina 248
CA - Canada 237
AT - Austria 203
UA - Ucraina 155
ID - Indonesia 147
MX - Messico 140
IQ - Iraq 121
EC - Ecuador 115
JP - Giappone 114
PK - Pakistan 102
PL - Polonia 89
PH - Filippine 87
CO - Colombia 84
ES - Italia 83
CI - Costa d'Avorio 81
KR - Corea 77
BE - Belgio 74
CZ - Repubblica Ceca 74
MA - Marocco 60
VE - Venezuela 60
CL - Cile 54
UZ - Uzbekistan 53
SA - Arabia Saudita 46
PY - Paraguay 45
TH - Thailandia 44
KE - Kenya 42
TN - Tunisia 38
JO - Giordania 37
MY - Malesia 36
IR - Iran 34
TW - Taiwan 30
LT - Lituania 29
AZ - Azerbaigian 28
EG - Egitto 28
KZ - Kazakistan 25
PE - Perù 25
AU - Australia 24
ET - Etiopia 24
RO - Romania 23
BO - Bolivia 22
AE - Emirati Arabi Uniti 20
JM - Giamaica 19
UY - Uruguay 19
GR - Grecia 18
IL - Israele 18
NP - Nepal 18
BG - Bulgaria 15
CR - Costa Rica 15
HN - Honduras 14
LU - Lussemburgo 14
OM - Oman 14
CH - Svizzera 13
PA - Panama 13
AL - Albania 12
BH - Bahrain 12
PS - Palestinian Territory 12
DO - Repubblica Dominicana 11
DZ - Algeria 11
SN - Senegal 10
LB - Libano 9
SI - Slovenia 9
SY - Repubblica araba siriana 9
BY - Bielorussia 8
GE - Georgia 8
GT - Guatemala 8
NG - Nigeria 8
RS - Serbia 8
SV - El Salvador 8
TT - Trinidad e Tobago 8
BB - Barbados 7
DK - Danimarca 7
KG - Kirghizistan 7
PT - Portogallo 7
QA - Qatar 7
BA - Bosnia-Erzegovina 6
HU - Ungheria 6
KW - Kuwait 6
LV - Lettonia 6
MD - Moldavia 6
AM - Armenia 5
KH - Cambogia 5
Totale 46.869
Salva come PNG Salva come JPEG
Città #
Singapore 3.303
Ashburn 2.185
San Jose 1.883
Chandler 1.715
Dublin 1.659
Dallas 1.317
Hong Kong 1.264
Beijing 879
Santa Clara 871
Ho Chi Minh City 839
Boardman 639
Hanoi 609
Johannesburg 551
New York 508
Parma 486
Los Angeles 426
Lauterbourg 412
Ann Arbor 363
Princeton 359
Shanghai 331
Council Bluffs 311
Munich 260
Dearborn 258
Nanjing 194
Des Moines 184
Helsinki 179
Milan 178
Wilmington 175
Buffalo 171
São Paulo 170
Vienna 164
Moscow 163
Hefei 160
Columbus 152
Izmir 142
Jacksonville 133
Bologna 126
Da Nang 123
Chicago 112
Seattle 112
Haiphong 105
Bremen 101
Jakarta 99
The Dalles 97
Marseille 96
Rome 93
Frankfurt am Main 89
Jinan 86
Tokyo 85
Rio de Janeiro 84
Abidjan 81
Toronto 78
San Mateo 74
Nuremberg 73
Warsaw 70
London 69
Shenyang 64
Montreal 63
Turku 63
Amsterdam 62
Atlanta 62
Brussels 62
Denver 60
Nanchang 60
Redmond 59
Tianjin 59
Guangzhou 58
Chennai 57
Kunming 56
Orem 55
Hebei 53
Brooklyn 52
Naples 52
Belo Horizonte 51
Houston 51
Fremont 50
Brno 49
Changsha 48
Phoenix 48
Baghdad 47
Biên Hòa 47
Hải Dương 46
Modena 45
Tashkent 44
Curitiba 43
Bengaluru 42
Mexico City 42
Poplar 42
Seoul 41
Stockholm 41
Pune 40
San Francisco 39
Boston 38
Norwalk 38
Verona 37
Dhaka 36
Quito 36
Brasília 34
Nairobi 34
Amman 33
Totale 27.585
Salva come PNG Salva come JPEG
Nome #
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 264
LINFOCITI INFILTRANTI IL TUMORE, BAP-1, VEGFR-2 E IGF-1R NEL MESOTELIOMA PLEURICO MALIGNO 261
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 251
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 247
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 244
238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors 238
1328P Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients 218
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 215
Validation of a radiomic approach to decipher NSCLC immune microenvironment in surgically resected patients 213
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 211
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 208
Isolation and characterization of circulating tumor cells in advanced squamous-cell carcinoma of the lung 207
Low PD-1 expression in Cytotoxic CD8+ Tumor infiltrating Lymphocytes Confers an Immune Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value 204
Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib 204
227P Sexual dimorphism in immune profile of early and advanced NSCLC 202
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy 202
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 201
Longitudinal Changes of CT-radiomic and Systemic Inflammatory Features Predict Survival in Advanced Non–Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors 197
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 197
The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors 195
INTEGRATION OF TISSUE PD-1/PD-L1 IMMUNE CHECKPOINT WITH COMPUTED TOMOGRAPHY (CT) BASED TEXTURE ANALYSIS EXHIBITS HIGH PROGNOSTIC IMPACE ON SURGICALLY RESECTED NON SMALL CELL LUNG CANCER (NSCLC) 194
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 193
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 192
First-line immunotherapy in non-small cell lung cancer patients with poor performance status: A systematic review and meta-analysis 191
Characterization of gefitinib uptake in NSCLC cell lines 190
Accuracy of fine needle aspiration cytology in the pathological typing of non-small cell lung cancer. 187
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 185
Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method 185
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS 184
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 180
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC 179
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC 178
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 178
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 177
Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 176
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors 176
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 175
INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A multicenter prospective observational study (INVIDIa-2) 175
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 174
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 174
Dataset on the identification of a prognostic radio-immune signature in surgically resected Non Small Cell Lung Cancer 173
CLINICAL PREDICTORS OF 30-DAY MORTALITY IN HOSPITALIZED PATIENTS WITH LUNG CANCER: A RETROSPECTIVE SINGLE-CENTER OBSERVATIONAL STUDY 172
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 171
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 171
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 170
ACCURACY OF CYTOLOGY IN THE IDENTIFICATION OF HISTOLOGIC SUBTYPE IN NON-SMALL CELL LUNG CANCER (NSCLC 168
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 167
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 167
Emergence of a HER2-amplified clone during disease progression in an ALK-rearranged NSCLC patient treated with ALK-inhibitors: A case report 167
The role of miRNA-221 and miRNA-126 in patients with benign metastasizing leiomyoma of the lung: an overview with new interesting scenarios 165
Isolation and characterization of H23 clones resistant to the KRASG12C inhibitors sotorasib and adagrasib 163
Advantages of multidetector row CT with multiplanar reformation in guiding percutaneous lung biopsies. 163
Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial 163
Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature 162
Widespread Nivolumab-induced Enteropathy in a Long Responder Non–Small-cell Lung Cancer Patient 161
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 160
Neoplasie del polmone in Neoplasie del Distretto Toracico 159
Integrated MRI–Immune–Genomic Features Enclose a Risk Stratification Model in Patients Affected by Glioblastoma 158
Aberrant expression of PTEN in squamous lung cancer cells: molecular analysis and impact on the synergistic combination of the targeted therapy with BKM120 and Defactinib 158
CDK4/6 inhibitors overcome resistance to osimertinib in NSCLC cell lines independently from resistance mechanisms 158
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 158
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients 157
Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens 157
ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients 157
IASLC and WHO 2004 Grading System as Prognostic Factors in 492 Cases of Pulmonary Adenocarcinoma 156
CT-guided biopsy of pulmonary nodules: Is pulmonary hemorrhage a complication or an advantage? 156
Prognostic value of [18F]FDG PET/CT parameters in surgically resected primary lung adenocarcinoma: a single-center experience 156
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 155
Gefitinib metabolism by CYP1A1 affects biological responses in NSCLC cell lines. 155
CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients 154
From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC 154
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors 153
Spatial architecture of tumour-infiltrating lymphocytes as a prognostic parameter in resected non-small-cell lung cancer 152
Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint Inhibitors 151
Integrated CT imaging and tissue immune features disclose a radio-immune signature with high prognostic impact on surgically resected NSCLC 151
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 151
Unraveling the link between cholesterol and immune system in cancer: From biological mechanistic insights to clinical evidence. A narrative review 148
Predictive factors of diagnostic accuracy of CT-guided transthoracic fine-needle aspiration for solid noncalcified, subsolid and mixed pulmonary nodules. 148
Multiple primary malignancies involving lung cancer: a single-center experience 147
Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC) 146
Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC 145
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 145
Reliability of EGFR and KRAS mutation analysis on fine-needle aspiration washing in non-small cell lung cancer 145
2125P Potential ROle of hypoVItaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): A prospective observational study 144
Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives 144
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study 144
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The practice study 144
SMO mutations confer poor prognosis in malignant pleural mesothelioma 144
Semiautomatic analysis on computed tomography in locally advanced or metastatic non-small cell lung cancer: Reproducibility and Prognostic Significance of Unidimensional and 3-dimensional Measurements. 143
Curved Needles in CT-Guided Fine Needle Biopsies of Abdominal and Retroperitoneal Small Lesions 143
L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib 143
P1.15-04 Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 142
Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient 142
Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs) 142
Overexpression of microRNA‑486 affects the proliferation and chemosensitivity of mesothelioma cell lines by targeting PIM1 141
ANALYSIS OF MICRORNA EXPRESSION IN MALIGNANT PLEURAL MESOTHELIOMA, ASBESTOSIS AND BENIGN PULMONARY DISEASE: A PRELIMINARY STUDY 140
Transthoracic computed tomography-guided lung biopsy in the new era of personalized medicine 140
Longitudinal blood immune-inflammatory and radiomic profiling to decode different patterns acquired resistance to immunotherapy in patients with NSCLC 139
Monitoring cfDNA in plasma and in other liquid biopsies of advanced EGFR mutated NSCLC patients: A pilot study and a review of the literature 139
Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with Nivolumab 138
Totale 17.227
Salva come PNG Salva come JPEG
Categoria #
all - tutte 179.280
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 179.280
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202180 0 0 0 0 0 0 0 0 0 0 0 80
2021/20221.834 56 32 60 101 51 34 304 136 82 41 134 803
2022/20236.278 806 675 367 428 518 681 70 410 1.991 28 219 85
2023/20242.925 134 199 90 89 288 652 209 199 127 195 256 487
2024/20259.002 220 570 662 514 913 879 452 376 1.079 913 757 1.667
2025/202623.348 1.715 1.799 2.944 2.197 3.262 1.210 2.371 829 2.880 1.737 1.530 874
Totale 47.734